Dr. Gregory E. Holt, MD

Dr. Holt practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Holt's NPI, 1104936483, was assigned on August 30, 2006. Dr. Holt graduated from Loyola University Chicago Stritch School of Medicine in 2002. Dr. Holt holds Florida license ME 108849.

Dr. Holt's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Holt's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Holt is also affiliated with Jackson Memorial Hospital. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Holt practices, 2 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Holt's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Holt is board certified in critical care medicine by the American Board of Internal Medicine. Dmand AI has Dr. Holt's licenses on file in 3 states: Florida, Washington and Virginia.

Dmand AI lists asthma, chronic obstructive pulmonary disease (COPD) and tobacco use among the conditions Dr. Holt treats.

CMS data shows 114 Medicare services from Dr. Holt across 4 procedure codes in 2024, for 70 Medicare patients. Medicare paid $13,760 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 70 Medicare patients who saw Dr. Holt in 2024. The largest group is 75 to 84, with 27 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 47% are also on Medicaid. Their average risk score is 2.84, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Holt's median patient age at 73, with 50% women.

In 2024, Dr. Holt wrote 369 Medicare Part D claims for 47 patients. 40% of them were for generic drugs. CMS names the drug for 277 of them, across 13 drugs with 11 or more claims each, at $74,609 in total drug cost. In 2023, CMS named 291 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Holt for performance year 2024, reported as part of a group. Dr. Holt accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Holt as offering telehealth.

Dmand AI links 36 papers to Dr. Holt, published from 2011 to 2024. 2020 was the busiest year, with 6. The most frequent topics are COVID-19, Lung and Antibodies, Monoclonal, Humanized. Dr. Holt has published most often in Ann Am Thorac Soc. Dr. Holt's most frequent co-authors are Mehdi Mirsaeidi, MD, Michael A. Campos, MD and Rafael Alejandro Calderon-Candelario, MD.

Dmand AI links Dr. Holt to 3 clinical trials. Conditions studied include COVID-19, Pulmonary Emphysema and Severe Acute Respiratory Syndrome.

CMS Open Payments shows 53 general payments to Dr. Holt from 11 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 38% of the total. Intuitive Surgical, Inc. paid the most, $8,657.

Dmand AI lists 1 award for Dr. Holt, most recently CMS Stage 1 EHR in 2012.

Dr. Holt graduated from Loyola University Chicago Stritch School of Medicine in 2002.

Dr. Holt is in network with 11 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.